Latest Theravance (THRX) Headlines
Patient Recruitment Completes in Landmark RELVAR(R)/BREO(R) ELLIPTA(R) Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
Marketwire - Thu Mar 13, 7:02AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the "Study to Understand Mortality and MorbidITy", known as SUMMIT, has completed enrolment. The aim of this study, which has now enrolled approximately 16,000 patients, is to determine the impact of Relvar(R)/Breo(R) Ellipta(R) (fluticasone furoate 'FF'/vilanterol 'VI') on all cause mortality amongst patients with moderate chronic obstructive pulmonary disease (COPD) who have cardiovascular disease (CVD) or are at increased risk for CVD.
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Theravance to Split in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 11:00AM CST
Theravance will split into two independent companies in the second quarter.
Theravance Announces Update to Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharmaceutical Operations
Marketwire - Mon Mar 03, 3:56PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that its plan to separate its businesses into two independent, publicly traded companies is now expected to be completed during the second quarter 2014. This decision was reached following a review of the expected timelines for completion of third party activities. The company had previously communicated that the separation would occur in early 2014.
Update on Teva's DuoResp Spiromax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 5:00PM CST
The EMA's CHMP provided a positive opinion on the approval of Teva's DuoResp Spiromax inhalation powder.
Theravance to Present at Investor Conferences in March 2014
Marketwire - Tue Feb 25, 3:06PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Theravance management is scheduled to present at the following investor conferences in March 2014:
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CHMP Positive on Glaxo's Two Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:45PM CST
GlaxoSmithKline announced that Incruse and Anoro have received a positive opinion from the CHMP.
Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD
M2 - Fri Feb 21, 5:02AM CST
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol (UMEC/VI) under the proposed brand name Anoro ® as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Insider Trading Alert - AWAY, THRX And TWTC Traded By Insiders
at The Street - Thu Feb 20, 9:45AM CST
Stocks with insider trader activity include AWAY, THRX and TWTC
Anoro(R) (umeclidinium / vilanterol) Receives Positive Opinion From the CHMP in Europe for the Treatment of COPD
Marketwire - Thu Feb 20, 6:59AM CST
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol (UMEC/VI) under the proposed brand name Anoro(R) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
5 Stocks Insiders Love Right Now
at The Street - Wed Feb 19, 11:49AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
Insider Trading Alert - SPLK, ARE And THRX Traded By Insiders
at The Street - Fri Feb 14, 9:30AM CST
Stocks with insider trader activity include SPLK, ARE and THRX
UPDATE: The Gate Opens New World of Creative Space for Art, Tech, Maker Community
Marketwire - Thu Feb 13, 12:13PM CST
When is a commercial building not just a commercial building? When it creates a disruptive, new definition for a place to work. In short: The Gate. Animated by the creative energy of its artists-in-residence, tech-startup visionaries, and makers of all stripes, The Gate is simply not like other commercial buildings. Well, it is, perhaps, reminiscent of such earlier, precedent-setting New York City landmarks as the iconic Brill Building, where, the art and business of music was turned on its ear, or The Factory, where Warhol and friends lived and breathed entirely new art forms. It also takes a digital page from Silicon Valley's Xerox PARC and all those suburban garages, where things like mice and killer apps were invented and then went on to ignite -- and change -- the world.
A Closer Look at 4 Potential Blockbuster Drugs of 2014
Leo Sun, The Motley Fool - Motley Fool - Thu Feb 13, 9:21AM CST
In the biotech and pharmaceutical industries, future expected sales of new and experimental drugs are just as important as sales of current ones. Newer drugs are needed to diversify portfolios away from single top sellers and fill in the holes left...
Loss at Theravance Wider Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 11:10AM CST
Theravance's fourth quarter loss was wider than the Zacks Consensus Estimate.
Barbarian At The Gate: Theravance (THRX)
at The Street - Fri Feb 07, 8:54AM CST
Trade-Ideas LLC identified Theravance (THRX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Theravance Reports 2013 Financial Results
Marketwire - Thu Feb 06, 3:10PM CST
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the fourth quarter and full year ended December 31, 2013. Revenue for the fourth quarter and full year of 2013 was $1.6 million and $4.8 million, respectively. Net loss for the fourth quarter and full year of 2013 was $49.9 million and $170.7 million, respectively. Net loss per basic and diluted share was $0.46 and $1.67 for the fourth quarter and full year of 2013, respectively. Cash and cash equivalents, short-term investments and marketable securities totaled $520.5 million as of December 31, 2013.
Theravance to Present at the Leerink Global Healthcare Conference
Marketwire - Thu Jan 30, 3:05PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014, at 8:30 a.m. EST. The conference will be held from February 12 - 13, 2014 at the Waldorf Astoria, New York, NY.
Theravance Appoints Frank Pasqualone Senior Vice President, Operations
Marketwire - Thu Jan 23, 3:05PM CST
Theravance, Inc. (NASDAQ: THRX) announced today the appointment of Frank Pasqualone, Senior Vice President, Operations. Mr. Pasqualone will report directly to Rick E Winningham, Chief Executive Officer.
Patient Recruitment Completes in Landmark RELVAR(R)/BREO(R) ELLIPTA(R) Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
Marketwire - Thu Mar 13, 7:02AM CDT
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the "Study to Understand Mortality and MorbidITy", known as SUMMIT, has completed enrolment. The aim of this study, which has now enrolled approximately 16,000 patients, is to determine the impact of Relvar(R)/Breo(R) Ellipta(R) (fluticasone furoate 'FF'/vilanterol 'VI') on all cause mortality amongst patients with moderate chronic obstructive pulmonary disease (COPD) who have cardiovascular disease (CVD) or are at increased risk for CVD.
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Theravance to Split in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 11:00AM CST
Theravance will split into two independent companies in the second quarter.
Theravance Announces Update to Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharmaceutical Operations
Marketwire - Mon Mar 03, 3:56PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that its plan to separate its businesses into two independent, publicly traded companies is now expected to be completed during the second quarter 2014. This decision was reached following a review of the expected timelines for completion of third party activities. The company had previously communicated that the separation would occur in early 2014.
Update on Teva's DuoResp Spiromax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 5:00PM CST
The EMA's CHMP provided a positive opinion on the approval of Teva's DuoResp Spiromax inhalation powder.
Theravance to Present at Investor Conferences in March 2014
Marketwire - Tue Feb 25, 3:06PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Theravance management is scheduled to present at the following investor conferences in March 2014:
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CHMP Positive on Glaxo's Two Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:45PM CST
GlaxoSmithKline announced that Incruse and Anoro have received a positive opinion from the CHMP.
Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD
M2 - Fri Feb 21, 5:02AM CST
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol (UMEC/VI) under the proposed brand name Anoro ® as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Insider Trading Alert - AWAY, THRX And TWTC Traded By Insiders
at The Street - Thu Feb 20, 9:45AM CST
Stocks with insider trader activity include AWAY, THRX and TWTC
Anoro(R) (umeclidinium / vilanterol) Receives Positive Opinion From the CHMP in Europe for the Treatment of COPD
Marketwire - Thu Feb 20, 6:59AM CST
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol (UMEC/VI) under the proposed brand name Anoro(R) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
5 Stocks Insiders Love Right Now
at The Street - Wed Feb 19, 11:49AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
Insider Trading Alert - SPLK, ARE And THRX Traded By Insiders
at The Street - Fri Feb 14, 9:30AM CST
Stocks with insider trader activity include SPLK, ARE and THRX
UPDATE: The Gate Opens New World of Creative Space for Art, Tech, Maker Community
Marketwire - Thu Feb 13, 12:13PM CST
When is a commercial building not just a commercial building? When it creates a disruptive, new definition for a place to work. In short: The Gate. Animated by the creative energy of its artists-in-residence, tech-startup visionaries, and makers of all stripes, The Gate is simply not like other commercial buildings. Well, it is, perhaps, reminiscent of such earlier, precedent-setting New York City landmarks as the iconic Brill Building, where, the art and business of music was turned on its ear, or The Factory, where Warhol and friends lived and breathed entirely new art forms. It also takes a digital page from Silicon Valley's Xerox PARC and all those suburban garages, where things like mice and killer apps were invented and then went on to ignite -- and change -- the world.
A Closer Look at 4 Potential Blockbuster Drugs of 2014
Leo Sun, The Motley Fool - Motley Fool - Thu Feb 13, 9:21AM CST
In the biotech and pharmaceutical industries, future expected sales of new and experimental drugs are just as important as sales of current ones. Newer drugs are needed to diversify portfolios away from single top sellers and fill in the holes left...
Loss at Theravance Wider Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 11:10AM CST
Theravance's fourth quarter loss was wider than the Zacks Consensus Estimate.
Barbarian At The Gate: Theravance (THRX)
at The Street - Fri Feb 07, 8:54AM CST
Trade-Ideas LLC identified Theravance (THRX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Theravance Reports 2013 Financial Results
Marketwire - Thu Feb 06, 3:10PM CST
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the fourth quarter and full year ended December 31, 2013. Revenue for the fourth quarter and full year of 2013 was $1.6 million and $4.8 million, respectively. Net loss for the fourth quarter and full year of 2013 was $49.9 million and $170.7 million, respectively. Net loss per basic and diluted share was $0.46 and $1.67 for the fourth quarter and full year of 2013, respectively. Cash and cash equivalents, short-term investments and marketable securities totaled $520.5 million as of December 31, 2013.
Theravance to Present at the Leerink Global Healthcare Conference
Marketwire - Thu Jan 30, 3:05PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014, at 8:30 a.m. EST. The conference will be held from February 12 - 13, 2014 at the Waldorf Astoria, New York, NY.
Theravance Appoints Frank Pasqualone Senior Vice President, Operations
Marketwire - Thu Jan 23, 3:05PM CST
Theravance, Inc. (NASDAQ: THRX) announced today the appointment of Frank Pasqualone, Senior Vice President, Operations. Mr. Pasqualone will report directly to Rick E Winningham, Chief Executive Officer.
